It is conceivable that osteosarcoma with KRAS WT can still be affected by daraxonrasib, and that increasing concentrations of daraxonrasib may inhibit the invasive ability of osteosarcomas with wild-type KRAS. Here, KRAS is linked to osteosarcoma.